Ngisho nokuhlinzwa, i-radiotherapy, i-chemotherapy, kanye/noma ukwelashwa okuhloswe kofuzo (okufana ne-cetuximab), izinga lokusinda leminyaka emihlanu lomdlavuza wekhanda nentamo othuthuke kakhulu ungama-46% kuphela. Ngokuvamile, ukwelashwa kuhle ekuqaleni, kodwa ukukhula komdlavuza kungaholela ekungazweni nomuthi.
Abacwaningi e-University of Colorado Cancer Center bathole ukuthi izakhi zofuzo ezimbili ezihlobene nokukhula kobuchopho kwasekuqaleni, kodwa ukuthula ezicutshini zabantu abadala abanempilo kubangela ukumelana namasampula wesimila. Isakhi sofuzo yi-EphB4 kanti isakhi sofuzo esihambisana nayo yi-ephrin-B2. Zombili izakhi zofuzo zizokhuphuka ngemuva kokuthi isiguli sihlulekile ukwelashwa, ngakho-ke ungazikhomba ukuze ubone ukuthi kusebenza kahle yini.
Kuze kube manje, basebenzise izicubu zesimila ezigulini ezibuyele emuva ukuze zikhule kumagundane. Amagundane abe esehlukaniswa ngamaqembu okwelapha, amanye athola i-chemotherapy cisplatin, amanye athola umuthi we-anti-EGFR i-cetuximab, kanti amanye athola ukwelashwa ngemisebe yodwa noma ngaphezu kwalokhu kwelashwa. Engeza imithi yokuhlola ye-EphB4-efrin-B2 inhibitor eqenjini elihlukile leqembu ngalinye.
Eqenjini le-cisplatin, ukusetshenziswa kwesimila sokwelashwa okusha kwe-inhibitor kwakungabonakali, kodwa ukungezwa kwe-EphB4-ephrin-B2 inhibitor ekwelapheni kwe-EGFR inhibitor cetuximab kwehlise kakhulu usayizi wesimila, futhi kwaba nenani elihle kakhulu lokusinda jikelele. Abacwaningi bakholelwa ukuthi i-EGFR ne-EphB4-efrin-B2 ingasetshenziswa njengezinye izindlela.
Ama-EphB4-efrin-B2 inhibitors njengamanje ahlolwa emitholampilo kweminye imidlavuza. Ucwaningo lwethu lubonisa ukuthi lungasetshenziswa ngempumelelo ngokuhlanganiswa nama-EGFR inhibitors ekwelapheni umdlavuza wekhanda nentamo othuthukile. I-Predictor ye-EphB4-efrin-B2 ingase ibhangqwe neziguli zesimila ezibonisa amazinga aphezulu alawa maprotheni.
